Workflow
LLY's Q4 Earnings Beat, Mounjaro, Zepbound Sales Fall Shy of Estimates
LLYLilly(LLY) ZACKS·2025-02-06 16:50

Core Insights - Eli Lilly and Company reported fourth-quarter 2024 adjusted earnings per share (EPS) of 5.32,exceedingtheZacksConsensusEstimateof5.32, exceeding the Zacks Consensus Estimate of 5.03, with a year-over-year increase of 114% [1] - Revenues for the quarter reached 13.53billion,a4513.53 billion, a 45% increase year-over-year, aligning with preliminary figures and surpassing the Zacks Consensus Estimate of 13.47 billion [1][2] Financial Performance - Adjusted earnings included a charge of 19 cents per share related to acquired in-process research and development [1] - Revenues benefited from a one-time payment of 300millionfromBoehringerIngelheimduetoacollaborationamendmentforJardiance[2]−Salesofkeygrowthproductsrose13300 million from Boehringer Ingelheim due to a collaboration amendment for Jardiance [2] - Sales of key growth products rose 13% to 5.95 billion, while new products contributed 5.64billiontorevenues[3]ProductSalesAnalysis−Mounjarosalesreached5.64 billion to revenues [3] Product Sales Analysis - Mounjaro sales reached 3.53 billion, a 60% increase year-over-year, but missed the Zacks Consensus Estimate of 3.88billion[5]−Zepboundrecordedsalesof3.88 billion [5] - Zepbound recorded sales of 1.91 billion, up from 1.26billioninthepreviousquarter,butalsofellshortofestimates[6]−Trulicitygeneratedrevenuesof1.26 billion in the previous quarter, but also fell short of estimates [6] - Trulicity generated revenues of 1.25 billion, down 25% year-over-year, primarily due to competitive dynamics [10] - Jardiance sales rose 50% to 1.2billion,benefitingfromtheone−timepayment,despitea11.2 billion, benefiting from the one-time payment, despite a 1% decline in U.S. revenues [11] - Taltz and Verzenio saw sales increases of 21% and 36% year-over-year, respectively, both exceeding estimates [12][13] Geographic Revenue Breakdown - U.S. revenues increased by 40% to 9.03 billion, while ex-U.S. revenues rose 55% to 4.50billion[4]Full−YearPerformance−Forthefullyear2024,salesrose324.50 billion [4] Full-Year Performance - For the full year 2024, sales rose 32% to 45.04 billion, slightly missing the Zacks Consensus Estimate of 45.22billion[16]−Adjustedearningsfor2024were45.22 billion [16] - Adjusted earnings for 2024 were 12.99 per share, up 105.5% year-over-year, beating the Zacks Consensus Estimate [17] Future Outlook - For 2025, Lilly expects revenues between 58.0billionand58.0 billion and 61.0 billion, indicating a year-over-year growth of 32% [18] - EPS for 2025 is projected to be in the range of 22.50to22.50 to 24.00, with the Zacks Consensus Estimate at $23.79 [18] - The company anticipates increased production of incretin medicines and the launch of new drugs to drive sales growth in 2025 [22][23]